BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dal Ben D, Lambertucci C, Buccioni M, Martí Navia A, Marucci G, Spinaci A, Volpini R. Non-Nucleoside Agonists of the Adenosine Receptors: An Overview. Pharmaceuticals (Basel) 2019;12:E150. [PMID: 31597388 DOI: 10.3390/ph12040150] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Nkomba G, Terre’blanche G, Janse van Rensburg HD, Legoabe LJ. Design, synthesis and evaluation of amino-3,5-dicyanopyridines and thieno[2,3-b]pyridines as ligands of adenosine A1 receptors for the potential treatment of epilepsy. Med Chem Res. [DOI: 10.1007/s00044-022-02908-9] [Reference Citation Analysis]
2 Catarzi D, Varano F, Vigiani E, Calenda S, Melani F, Varani K, Vincenzi F, Pasquini S, Mennini N, Nerli G, Dal Ben D, Volpini R, Colotta V. 4-Heteroaryl Substituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: Novel Insights on Structure-Activity Relationships and Perspectives. Pharmaceuticals (Basel) 2022;15:478. [PMID: 35455475 DOI: 10.3390/ph15040478] [Reference Citation Analysis]
3 Deganutti G, Barkan K, Ladds G, Reynolds CA. Multisite Model of Allosterism for the Adenosine A1 Receptor. J Chem Inf Model 2021;61:2001-15. [PMID: 33779168 DOI: 10.1021/acs.jcim.0c01331] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Catarzi D, Varano F, Colotta V. Special Issue "Adenosine Receptors as Attractive Targets in Human Diseases". Pharmaceuticals (Basel) 2021;14:140. [PMID: 33578687 DOI: 10.3390/ph14020140] [Reference Citation Analysis]
5 Spinozzi E, Baldassarri C, Acquaticci L, Del Bello F, Grifantini M, Cappellacci L, Riccardo P. Adenosine receptors as promising targets for the management of ocular diseases. Med Chem Res 2021;:1-18. [PMID: 33519168 DOI: 10.1007/s00044-021-02704-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Silvestro S, Schepici G, Bramanti P, Mazzon E. Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease. Molecules 2020;25:E5186. [PMID: 33171772 DOI: 10.3390/molecules25215186] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
7 Jacobson KA, IJzerman AP, Müller CE. Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets. Biochem Pharmacol 2021;187:114311. [PMID: 33130128 DOI: 10.1016/j.bcp.2020.114311] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
8 Dal Ben D, Antonioli L, Lambertucci C, Spinaci A, Fornai M, D'Antongiovanni V, Pellegrini C, Blandizzi C, Volpini R. Approaches for designing and discovering purinergic drugs for gastrointestinal diseases. Expert Opin Drug Discov 2020;15:687-703. [PMID: 32228110 DOI: 10.1080/17460441.2020.1743673] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]